Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ombrabulin - Sanofi

Next Previous
X
Search
Drug Profile

Ombrabulin - Sanofi

Alternative Names: AC 7700; AVE-8062; AVE8062A; RPR258063

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto
  • Developer Sanofi
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 01 Apr 2018 Sanofi terminates a phase I trial due to the occurrence of DLTs in cycle 1 in Solid tumours (Combination therapy) in Japan (IV)
  • 01 Nov 2014 Sanofi completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France, Italy, United Kingdom (NCT01193595)
  • 30 Nov 2013 Sanofi completes a phase I trial in Solid tumours in Japan (NCT01293630)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top